PharmaMar has requested the process of re-examination for Aplidin® from the EMA

0

(Pharmamar) PharmaMar (MSE:PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.

Leave A Reply

Your email address will not be published.